Heat Biologics, Inc.Find Ratings Reports
HEAT BIOLOGICS INC's gross profit margin for the third quarter of its fiscal year 2020 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. HEAT BIOLOGICS INC is extremely liquid. Currently, the Quick Ratio is 30.91 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 630.67% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY20||Q3 FY19|
|Net Sales ($mil)||0.85||0.01|
|Net Income ($mil)||-8.85||-6.2|
|Balance Sheet||Q3 FY20||Q3 FY19|
|Cash & Equiv. ($mil)||117.31||15.02|
|Total Assets ($mil)||129.71||24.45|
|Total Debt ($mil)||1.94||0.35|
|Profitability||Q3 FY20||Q3 FY19|
|Gross Profit Margin||-1036.82||-84350.0|
|Return on Assets||-17.68||-88.41|
|Return on Equity||-18.87||-129.97|
|Debt||Q3 FY20||Q3 FY19|
|Share Data||Q3 FY20||Q3 FY19|
|Shares outstanding (mil)||22.43||4.76|
|Div / share||0.0||0.0|
|Book value / share||5.42||3.49|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||4016505.0||3.0914426E7|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.11 indicates a significant discount versus the S&P 500 average of 4.11 and a significant discount versus the subsector average of 11.24. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, HEAT BIOLOGICS INC proves to trade at a discount to investment alternatives.
|HTBX NM||Peers 32.89||HTBX NM||Peers 87.81|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
HTBX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
HTBX's P/CF is negative making the measure meaningless.
|HTBX NM||Peers 21.08||HTBX NA||Peers 0.69|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
HTBX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|HTBX 1.11||Peers 11.24||HTBX 52.24||Peers 10.80|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
HTBX is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
HTBX is expected to have an earnings growth rate that significantly exceeds its peers.
|HTBX 31.17||Peers 1710.59||HTBX 39.76||Peers 695.47|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
HTBX is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
HTBX significantly trails its peers on the basis of sales growth.